Investor Presentation
Released
Released
Announcement PDF
1
Building a Portfolio
of Differentiated
Specialty Therapies
Investor Update | September 2026
Important Notice and Disclaimer
2
‣ Nature of Document: This presentation has been prepared and issued by LTR Pharma Ltd
(Company or LTP) to provide general information about the Company. The information in this
document is in summary form and should not be relied upon as a complete and accurate
representation of any matters that a reader should consider in evaluating the Company. While
management has taken every effort to ensure the accuracy of the material in this presentation,
the Company have not verified the accuracy or completeness of the material contained in this
presentation.
‣ Not an offer: This presentation is NOT a recommendation, offer or invitation to subscribe for or
purchase LTP securities. This presentation is not exhaustive and does not contain all of the
information a potential investor, or their professional advisers would require, and it does NOT
constitute a “Prospectus" or a "Disclosure Document” (as defined in the Corporations Act 2001
(Cth), and has not been, and will not be, lodged with the Australian Securities and Investments
Commission or any other regulatory authority. This presentation should not be distributed,
transmitted, or viewed by any person in any jurisdiction where the distribution, transmission or
viewing of this document would be unlawful under the securities or other laws of that or any
other jurisdiction. In particular, this presentation may not be released to US wire services or
distributed publicly in the United States. This presentation does not constitute an offer to sell, or
a solicitation of an offer to buy any securities in any jurisdiction. Any failure to comply with such
restrictions could constitute a violation of applicable securities laws.
‣ Not financial product advice: You should not act and should refrain from acting in reliance on this
presentation. Nothing contained in this presentation constitutes investment, legal, tax or other
advice. This presentation does not take into account the individual investment objectives, financial
situation and particular needs of potential investors. Before making a decision to invest in the
Company at any time, you should conduct, with the assistance of your broker or other financial or
professional adviser, your own investigation in light of your particular investment needs,
objectives and financial circumstances and perform your own analysis of the Company before
making any investment decision.
‣ Forward looking statements: This presentation contains forward-looking information about the
Company and its operations. In certain cases, forward-looking information may be identified by
such terms as "anticipates", "believes", “should”, "could", "estimates", “target”, “likely”, “plan”,
"expects", "may", “intend”, "shall", "will", or "would". These statements are based on information
currently available to the Company and the Company provides no assurance that actual results
will meet management's expectations. Forward-looking statements are subject to risk factors
associated with the Company’s business, many of which are beyond the control of the Company.
It is believed that the expectations reflected in these statements are reasonable but they may be
affected by a variety of variables and changes in underlying assumptions which could cause actual
results or trends to differ materially from those expressed or implied in such statements. There
can be no assurance that actual outcomes will not differ materially from these statements.
‣ Disclaimer: No representation or warranty, express or implied, is made by the Company that the
material contained in this presentation will be achieved or proved correct. Except for statutory
liability which cannot be excluded, the Company, its directors, officers, and employees expressly
disclaim any responsibility for the accuracy, fairness, sufficiency or completeness of the material
contained in this presentation and excludes all liability whatsoever (including in negligence) for
any loss or damage which may be suffered by any person as a consequence of any information in
this presentation or any effort or omission therefrom. The Company will not update or keep
current the information contained in this presentation or to correct any inaccuracy or omission
which may become apparent, or to furnish any person with any further information. Any opinions
expressed in the presentation are subject to change without notice.
‣ LTR Pharma Limited ACN 644 924 569
Executive Summary
3
Differentiated Lead Program – SPONTAN / ROXUS
Rapid-acting intranasal PDE5 therapy demonstrating ~6x faster absorption versus
oral tablets1 with a favourable safety and tolerability profile.
U.S. Commercial Launch & FDA Value Pathway
ROXUS® U.S. commercial launch targeted for H2 CY26, with definitive agreements
with Shed and Strive supporting the planned commencement of first U.S. commercial
revenues. In parallel, SPONTAN® is advancing through the FDA 505(b)(2) pathway
toward a single pivotal Phase III study.
Early Real-World Validation (Australia)
1,000+ prescriptions2 under the TGA Special Access Scheme (SAS), supporting
prescriber adoption and expanding real-world safety and efficacy data.
Strategic Partnerships
Co-development agreement with Aptar Pharma (NYSE). Commercial manufacturing
with Mayne Pharma (ASX). Australian distribution through EBOS/Symbion (ASX), and
U.S. commercial partnerships with Shed and Strive.
Funded Near-Term Execution
$19.6M cash and zero debt, supporting near-term U.S. commercial, clinical and
regulatory value inflection points.3
LTR Pharma: Late-stage pharmaceutical platform approaching U.S. commercialisation
Footnotes: 1) ~6x refers to median Tmax of ~10 minutes for SPONTAN (5 mg) versus ~60 minutes for oral vardenafil (20 mg), Phase II interim data; ASX
announcement 1 May 2026. 2.) As at 17 December 2025 (ASX: 17 Dec 2025) . 3) Appendix 4C for quarter ended 30 June 2026. Cash figures in Australian Dollars.
US Strategy: What FDA approval unlocks
503A enables rapid commercialisation today, while the FDA approval has the potential to
materially expand the addressable market and long-term commercial opportunity
ROXUS® - 503A SPONTAN® - 505(b)(2) approval
Rapid commercial launch and market validation Expanded commercial opportunity
✓ Rapid route to initial US revenues through cash-pay DTC and telehealth
channels
Efficient made-to-order manufacturing model with limited inventory
requirements
1 Regulatory protection and intellectual property
505(b)(2) pathway may provide regulatory exclusivity and strengthen intellectual property
protection through potential Orange Book listing
2 Broader commercial reach
FDA-approved labelling supports promotional claims, payer engagement and potential
reimbursement, expanding commercial opportunities
Scalable pharmaceutical supply
Commercial-scale manufacturing supports broader distribution channels and long-term
supply flexibility
Strategic partnering opportunities
An FDA-approved product may enhance licensing, partnering and ex-US expansion
opportunities via dossier
LTR’s phased US strategy is designed to generate near-term commercial momentum while creating the foundation for a significantly larger
long-term value opportunity
Generates commercial experience, physician adoption and real-world data
to support broader strategy
✓ Establishes early physician adoption, prescribing behaviour and
commercial proof points ahead of FDA approval
3
4
4
Illustrative of the potential benefits of FDA approval. Outcomes are not assured and are subject to regulatory and commercial factors.
✓
✓
✓
US Commercialisation: Definitive Agreements Executed for
ROXUS®
Two definitive agreements now in place spanning patient demand and pharmacy supply
DEMAND ENGINE
Shed Holdings LLC | Executed 17 Jul 2026
US direct-to-consumer telehealth platform: Mavrox
‣ First commercial route-to-market for ROXUS® in the United
States
‣ ROXUS live on Mavrox as hero product; patient waitlist
established
‣ Performance-based minimum commercial volume of 150,000
ROXUS® prescription units in the first 12 months from
Commercial Launch
‣ Two-year US DTC telehealth exclusivity from launch, subject to
performance
SUPPLY ENGINE
Strive Specialties Inc. | Executed 20 Jul 2026
Exclusive US 503A pharmacy and fulfilment partner
‣ Five-state 503A platform; nationwide compounding and
fulfilment licensure
‣ Exclusive US pharmacy fulfilment partner with established
provider and clinic networks
‣ Two-year exclusivity from Commercial Launch, subject to
ongoing performance
‣ LTR Pharma remains product owner, intellectual property holder
and formulation supplier
Binding commercial framework established across US patient acquisition and pharmacy fulfilment
5
US Commercialisation: Launch Strategy
6
Today
ROXUS® Commercial
Launch - 2H CY26
Revenue shared
across LTR Pharma,
Shed and Strive
under executed
commercial
agreements
12 Months Post Launch
SPONTAN® FDA
Pathway: Pivotal
Phase III – Targeted
1H CY27
U.S. FDA Submission –
Targeted 2H CY27
ROXUS ®
Key In-Flight Activities:
• Technology transfer
• Commercial inventory planning
• Manufacturing readiness
ROXUS ®
Volume and Pricing:
• Shed commitment to support not less
than 150,000 ROXUS® units during the
first 12 months
• LTP anticipates pricing will be in line
with other premium ED competitors
ROXUS ®
Capital-light US Penetration:
• Capital-light market entry for LTR
Pharma
• Shed actively promoting ROXUS® as a
differentiated ED product on their
platform
SPONTAN ®
FDA Approval for Commercial Scale:
• Unlocks pharma licensing
partnerships
• Expands U.S. commercial channels
• Expands the addressable U.S.
opportunity
• Supports scalable long-term U.S
revenue growth
ROXUS® –
first US penetration
SPONTAN® –
delivering commercial scale
Indicative timeline – not to scale
Clinical proof. U.S. launch approaching.
Expanding intranasal portfolio. Funded execution.
Why Invest in LTR Pharma
Intranasal Portfolio &
Capital Position
‣ SPONTAN® / ROXUS® leads a
growing intranasal portfolio;
OROFLOW® is an early platform
expansion beyond ED into
oesophageal motility disorders.
‣ $19.6M current cash, zero debt2
and disciplined capital allocation.
‣ Strategic partnerships across
development, manufacturing,
distribution and U.S.
commercialisation.
U.S. Commercial
Launch
‣ ROXUS® U.S. commercial launch
targeted for H2 CY26; definitive
agreements with Shed and Strive
establish the route-to-market and
launch preparations are underway.
‣ Shed commitment to support not
less than 150,000 ROXUS®
prescription units during the first 12
months from Commercial Launch.
‣ Designed to generate near-term
commercial validation ahead of FDA
approval.
Clear FDA Value
Pathway
‣ Advancing through the FDA
505(b)(2) pathway following
successful Pre-IND engagement,
requiring a single pivotal Phase III
study.
‣ FDA approval supports broader
commercial reach, scalable
pharmaceutical supply, potential
payer engagement and strategic
partnering opportunities.
Clinical Differentiation
‣ SPONTAN® / ROXUS®
demonstrates ~6x shorter median
Tmax versus oral vardenafil,
reinforced by Phase II interim data1
confirming rapid absorption and a
favourable safety profile across
adult and ≥65-year cohorts.
‣ Positioned for treatment-
experienced and difficult-to-treat
populations, including post-
prostatectomy patients.
Note: (1) Interim data based on preliminary analysis of 27 subjects. Full statistical analysis is ongoing. Refer to the ASX announcement for details. (2) Appendix 4C for quarter ended
30 June 2026. Cash figures in Australian Dollars.
7
Large ED Market with a Clear Treatment Gap
Oral PDE5 inhibitors remain first-line, but response and persistence limitations leave a sizeable unmet need
~US$5B
estimated annual global ED drug
market¹
~322M
men globally estimated to have ED in
2025¹
Treatment pathway and gap
1 Oral PDE5 inhibitors First-line therapy; delayed onset and high
discontinuation
2 30–35% inadequate
response
Higher failure rates in difficult-to-treat populations²
3 Invasive second-line
options
Intracavernosal injection utilisation has fallen >55-
fold from peak³
SPONTAN® / ROXUS®
Rapid-onset, non-invasive
PDE5 option
• Positioned across the broad ED market
• Supports patients seeking greater
spontaneity
• Provides a non-invasive option for
patients inadequately served by oral
therapy
• Positioned before invasive treatments
1) Frost & Sullivan, The Erectile Dysfunction Medicines Market, September 2023. 2) McMahon et al., BMJ 2006. 3) Gillman & Chung, ANZ Journal of Surgery 2026 (MBS data 1996–2024; in-
office, MBS-billed procedures only).
8
Phase II Data Reinforce Rapid and Predictable Pharmacokinetic Profile
Interim pharmacokinetic and safety dataset
Key interim findings
• Median Tmax ~10 minutes for SPONTAN® 5 mg
• Comparable PK across adult and ≥65-year
cohorts
• No evidence of drug accumulation following 5
days of repeat dosing
• No serious adverse events
• No Grade 3 or 4 treatment-emergent adverse
events
• No treatment-related discontinuations
SPONTAN® vs oral comparator
Parameter
SPONTAN®
5 mg intranasal
Vardenafil
20 mg oral
Median Tmax ~10 minutes
(10–15 min)
~60 minutes
(30–180 min)
Onset profile Rapid and consistent Slower, variable
Repeat dosing No accumulation
observed
Not assessed
Safety (interim) No serious or Grade
3/4 TEAEs
No serious or severe
TEAEs
Study designed in accordance with FDA Pre-IND guidance
Note: Interim data based on preliminary analysis of 27 subjects. Full statistical analysis is ongoing. Lower Cmax relative to oral comparator reflects lower dose. Refer to the ASX announcement
dated 1 May 2026 for full details.
9
~6x shorter median Tmax
10
Australian Early Access Provides Real-World Clinical
Validation
TGA Special Access Scheme | treatment-experienced real-world cohort
1,000+
prescriptions as at 17 Dec 2025¹
Expanding
prescriber adoption
Established
distribution and fulfilment infrastructure
Improved erectile hardness and/or achieving penetration² Real-world cohort of 147 treatment-experienced men
93% 42 of 45
Seeking greater convenience and
spontaneity
64% 56 of 87
Post-prostatectomy subgroup
Context: Only 28% of men report erections firm enough for
intercourse five years after radical prostatectomy.³
57% 58 of 102
Inadequate response to oral PDE5
therapy
Overall cohort: 68% (100 of 147) Non-prostatectomy subgroup: 73% (44 of 60)
Source: ASX announcement 11 August 2026 (147-patient real-world cohort). 1) As at 17 December 2025 (ASX announcement 17 December 2025). 2) Composite endpoint:
improved erectile hardness and/or achieving penetration; real-world observational data. 3) Penson DF, McLerran D, Feng Z, et al. J Urol 2008;179(5 Suppl):S40-4.
Encouraging real-world outcomes in treatment-experienced and difficult-to-treat populations, including men
inadequately served by oral PDE5 therapy and men following prostatectomy.
Combination product expertise
‣ Co-development agreement
with Aptar Pharma (NYSE)
‣ VP7 multidose nasal spray platform
‣ Integrated drug-device
development programme
Regulatory and development
‣ Extractables study completed
‣ Leachables study underway
‣ Human factors studies progressing
‣ Supporting FDA combination product
requirements
Global Co-Development Agreement
Aptar Pharma
11
Strategic significance
‣ Global supply and FDA expertise
‣ Alignment with 505(b)(2)
development pathway
‣ Established pharmaceutical partner
Strategic partnership driving regulatory
success and market readiness
Portfolio Overview
and Development
Focus
12
Lead Clinical Program ‣ TGA Early Access – ACTIVE
‣ FDA 505(b)(2) regulatory pathway
‣ Phase II PK Study – interim data released
‣ 503A Commercial partners secured (US)
Early Development
OROFLOW – Platform Expansion
‣ HREC-approved study; initiation pending hospital contract
sign-off
‣ First platform application beyond ED, in gastrointestinal
disease
‣ Capital prioritised to lead program
Strategic Investment
LevOmega
‣ Equity Investment – 43%
‣ Focused on development of nature-identical omega-3
products
‣ Separate development pathway and capital structure
‣ Complementary to LTR’s core intranasal programs
Validated Platform and
Expanding Men’s Health
Portfolio
Intranasal Sprays for Erectile
Dysfunction
Intranasal Spray for
Oesophageal Motility Disorders (OMD)
Nature-Identical omega-3 Products
Portfolio Expansion
KYZATREX®
‣ Exclusive pilot commercialisation agreement with Marius
Pharmaceuticals (US)
‣ FDA-approved oral testosterone therapy; initial Australian
patient access via the TGA Special Access Scheme
‣ Six-month evaluation period, with a right to negotiate an
exclusive Australian licence
Oral Therapy for Testosterone
Deficiency
Potential fast-acting, non-invasive treatment for a debilitating condition where many patients ultimately require invasive intervention.
OROFLOW® Expands the Intranasal Platform Beyond ED
13
First application of the platform in gastrointestinal disease
Significant Unmet Need
OMD can cause impaired swallowing and
painful oesophageal contractions, with many
patients ultimately requiring invasive
interventions including surgery, pneumatic
dilation or botulinum toxin injection.
Potential Non-Invasive
Treatment
OROFLOW® is designed as a fast-acting
intranasal treatment that may improve
oesophageal emptying, swallowing function
and eating-related chest pain, while avoiding
the need to swallow an oral tablet.
Platform Expansion & Market
Opportunity
First gastrointestinal application of LTR
Pharma's proprietary intranasal platform
approved for formal clinical evaluation,
addressing an OMD treatment market
projected to reach ~US$8.1B by 2034.
¹ Fact.MR, Ineffective Oesophageal Motility Treatment Market Analysis, 2024. OROFLOW® is an investigator-initiated study, independently led by Dr Wu. ASX announcement: 24 June 2026.
HREC-approved investigator-initiated study independently led by Dr Peter Wu, Director of St George Motility Services.
Cash in Bank
$19.6 million
Avg. Quarterly Net Operating
Outflow1
$2.8 million
Debt Position
Zero debt
Financial Position
14
Funded Value Inflection Points
Source: Appendix 4C for the quarter ended 30 June 2026. 1) Average net operating cash outflow per quarter over the twelve months to 30 June 2026. June 2026 quarter
net operating outflow: $4.4M. Cash figures in Australian Dollars
Disciplined capital management supporting clinical and commercial execution
1 ROXUS® U.S. Commercial Launch & First Revenues
Targeted H2 CY2026 U.S. commercial launch and commencement of first U.S. commercial revenues via the Section 503A pathway, subject to completion of launch-readiness
conditions.
2 SPONTAN® Final Phase II Data & FDA Readiness
Final Phase II PK analysis and submission-enabling activities supporting the FDA 505(b)(2) pathway.
Includes CMC package finalisation, human factors validation and related regulatory workstreams.
3 OROFLOW® Study Initiation
HREC approval received; initiation pending hospital contract sign-
off.
Initial clinical results to follow study commencement.
Supporting activities include CMC package finalisation, human factors validation, leachables and non-clinical toxicology.
Funded to deliver near-term U.S. commercial, clinical and regulatory value inflection points
Near-term catalysts spanning first U.S. commercial revenues, late-stage clinical development and platform expansion.
Key Milestones
Commercial and clinical catalysts driving key value inflection points
Achieved
‣ Phase II PK interim data reported
‣ Pre-IND meeting completed with FDA alignment
on development plan
‣ Extractables study completed
‣ 1,000+ prescriptions under TGA early access
‣ Clinical data published in European Journal of
Pharmaceutical Sciences
‣ Definitive U.S. commercial agreements
executed with Shed and Strive
Near-Term Catalysts
‣ ROXUS® – U.S. Commercial Launch and
First Revenues
Targeted U.S. commercial launch and commencement of
first U.S. commercial revenues via the Section 503A
pathway, subject to completion of launch-readiness
conditions.
H2 CY2026
‣ SPONTAN® – Final Phase II PK Data
Final Phase II PK data and statistical analysis supporting the
FDA 505(b)(2) regulatory pathway.
Q3 CY2026
‣ SPONTAN® – Submission-Enabling Activities
Completion of submission-enabling activities including CMC
package finalisation, human factors validation and related
regulatory workstreams.
H2 CY2026
‣ OROFLOW® – Study Initiation
HREC approval received; commencement pending hospital
contract sign-off.
Development Progression
‣ SPONTAN® – Pivotal Phase III
Planned commencement of pivotal Phase III study.
‣ SPONTAN® – U.S. FDA Submission
Planned U.S. FDA submission under the 505(b)(2)
pathway.
‣ OROFLOW® – Initial Clinical Results
Initial clinical results / proof-of-concept assessment
following study commencement.
15
Note: Timings are targets and subject to change
Contact
investors@ltrpharma.com www.ltrpharma.com
Authorised for release by the Board of Directors
Appendix
Supporting information
Current Treatments
18
Oral Phosphodiesterase-5 (PDE5)
inhibitors are first-line treatments
Product
Main
Brand(s)
Time before sexual
activity for dose
Approval
Date (US)
Generic
availability
Sildenafil Viagra 1 hour+ 1998 Yes
Tadalafil Cialis 1 hour+ 2003 Yes
Vardenafil
Levitra,
Staxyn
1 hour+ 2003/2010 Yes
Avanafil Stendra 30 minutes+ 2012 Yes
Issues with oral
PDE5 inhibitors
Does not work for 30-35% of patients¹
Long response time of 1 hour + affects spontaneity
Adverse reactions in up to 35% of patients3
= High discontinuation rate
And when orals fail, the next
options are rarely used
Injections (ICI): use down >55-fold from peak²
Prosthesis surgery: ~3.6 per 100,000 men²
1) McMahon et al., BMJ 2006. 2) Gillman & Chung, ANZ Journal of Surgery 2026 (MBS data 1996-2024; in-office, MBS-billed procedures only). 3) Carvalheira et al., J Sex Med 2012.
Oral PDE5 inhibitors and SPONTAN® Nasal Spray
First and only PDE5 nasal spray, available now in Australia under TGA early access.
Parameter
SPONTAN®
Phase I Pharmacokinetic Study
19
‣ SPONTAN® nasal spray achieved rapid absorption
compared to oral PDE5 inhibitors.
‣ SPONTAN® delivered similar bioavailability (Cmax)
at half the dose of oral PDE5 inhibitors.
‣ Significantly faster (Tmax) with SPONTAN® in as little
as 9 min (avg. 12 min) vs oral (56 min) - longest 2.5 hours.
‣ Confirmed safety and tolerability profile of
SPONTAN® vs oral dosing PDE5 Inhibitors.
‣ SPONTAN® demonstrated more consistent
dosing than oral PDE5 Inhibitors.
‣ Phase I findings reproduced and extended in the
Phase II interim dataset.
Rapid absorption, consistent delivery
and favourable safety profile
‣ Cmax (ng/ml)
(5mg)
Vardenafil
(10mg) oral
‣ 13.0 ‣ 16.7
‣ Adverse Events ‣ 0 ‣ 1
‣ Tmax (min) ‣ 12 (range 9-15) 56 (Longest 150)
Source: SPONTAN Phase I Final Study Report, ASX announcement 14 October 2024; published in the European Journal of Pharmaceutical Sciences (ASX announcement
20 August 2025). Oral comparator: vardenafil 10 mg.
Prevalence of ED with individuals with cardiovascular risk factors,
hypertension and diabetes, is reported as high as 50%
Understanding
the Market Need
20
A significant healthcare
challenge affecting
relationships and
quality of life
Physical causes
‣ Heart health
‣ Hormone balance
‣ Prostate Cancer
‣ Diabetes
‣ Medical treatments
‣ Hair loss
‣ Weight loss
‣ Antidepressants
Psychological Impact
‣ Relationship problems
‣ Mental wellbeing
‣ Day to day stress
60%
50%
Growing prevalence with
age impacts quality of life
Of men over
45 experience ED2
Stop purchasing
PDE5 tablets1
1) Carvalheira et al., "Dropout in the Treatment of Erectile Dysfunction with PDE5: A Study on Predictors and a Qualitative Analysis of Reasons for Discontinuation,"
Journal of Sexual Medicine, May 2012. 2) Source: Frost and Sullivan Report, The Erectile Dysfunction Medicines Market, September 2023. 3) Selvin E, Burnett AL, Platz
EA. Prevalence and risk factors for erectile dysfunction in the US. Am J Med 2007;120:151-7.
in Key Markets
21
As risk factors become more prevalent, so does ED
Source: Frost and Sullivan Report, The Erectile Dysfunction Medicines Market, September 2023
~30m ~33m ~150m
60.7%
of males 45y/o+
USA
EU
China
Aus
Share your feedback
Discover